{
    "organizations": [],
    "uuid": "221222d28359e0358570e2876c4660432489079b",
    "author": "",
    "url": "https://www.reuters.com/article/brief-adverum-biotechnologies-announces/brief-adverum-biotechnologies-announces-completion-of-dosing-of-first-cohort-idUSASB0C7FR",
    "ord_in_thread": 0,
    "title": "BRIEF-Adverum Biotechnologies Announces Completion Of Dosing Of First Cohort",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 26, 2018 / 2:12 PM / Updated 7 minutes ago BRIEF-Adverum Biotechnologies Announces Completion Of Dosing Of First Cohort Reuters Staff 1 Min Read Feb 26 (Reuters) - Adverum Biotechnologies Inc: * ADVERUM BIOTECHNOLOGIES ANNOUNCES COMPLETION OF DOSING OF FIRST COHORT OF PATIENTS IN THE ADVANCE PHASE 1/2 CLINICAL TRIAL OF ADVM-043 GENE THERAPY FOR A1AT DEFICIENCY * ADVANCE TRIAL CONTINUES ON TRACK, EXPECT TO REPORT PRELIMINARY DATA IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage:",
    "published": "2018-02-26T16:10:00.000+02:00",
    "crawled": "2018-02-26T16:23:59.007+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "updated",
        "minute",
        "ago",
        "biotechnology",
        "announces",
        "completion",
        "dosing",
        "first",
        "cohort",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "adverum",
        "biotechnology",
        "inc",
        "adverum",
        "biotechnology",
        "announces",
        "completion",
        "dosing",
        "first",
        "cohort",
        "patient",
        "advance",
        "phase",
        "clinical",
        "trial",
        "gene",
        "therapy",
        "a1at",
        "deficiency",
        "advance",
        "trial",
        "continues",
        "track",
        "expect",
        "report",
        "preliminary",
        "data",
        "second",
        "half",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}